Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Studying Dilated cardiomyopathy
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Wayne State University
- Principal Investigator
- Steven E Lipshultz, MDWayne State University
- Enrollment
- 288 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2013 – 2022
Study locations (13)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Children's Hospital of New York, Columbia Presbyterian Medical Center, New York, New York, United States
- Children's Hospital at Montefiore, The Bronx, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh of UMPC, Pittsburgh, Pennsylvania, United States
- Le Bonheur Children's Hospital, Memphis, Tennessee, United States
- Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States
- Primary Children's Medical Center, Salt Lake City, Utah, United States
- Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada
Collaborators
Carelon Research · Washington University School of Medicine · Boston Children's Hospital · Columbia University · Children's Hospital of Philadelphia · Ann & Robert H Lurie Children's Hospital of Chicago · Primary Children's Hospital · Monroe Carell Jr. Children's Hospital at Vanderbilt · Stollery Children's Hospital · Children's Hospital Medical Center, Cincinnati · Montefiore Medical Center · Children's Hospital Colorado · Le Bonheur Children's Hospital · University of Pittsburgh
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01873976 on ClinicalTrials.govOther trials for Dilated cardiomyopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07137338A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated CardiomyopathyRocket Pharmaceuticals Inc.
- RECRUITINGNCT07293338Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated CardiomyopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1NCT07241104A Study of AZD4063 in PLN R14del Dilated CardiomyopathyAstraZeneca
- RECRUITINGNANCT07359690Multimodal Analysis of Endomyocardial BiopsiesUniversity Hospital, Essen
- RECRUITINGPHASE1NCT06464588A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)Emory University
- RECRUITINGNANCT06922851Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06741995Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated CardiomyopathyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT06688396Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)Lancaster General Hospital